Processa Pharmaceuticals (PCSA) Long-Term Deferred Tax (2012 - 2021)
Processa Pharmaceuticals' (PCSA) quarterly Long-Term Deferred Tax came in at $31.4 million in Q4 2021, up 54.35% YoY from $20.4 million in Q4 2020, and up 54.35% on a QoQ basis from $20.4 million in Q4 2020.
Processa Pharmaceuticals (PCSA) Long-Term Deferred Tax (2012 - 2021) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 10 years of Long-Term Deferred Tax data on file, last reported at $31.4 million in Q4 2021.
- Quarterly Long-Term Deferred Tax rose 54.35% year-over-year to $31.4 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $31.4 million (up 54.35% YoY) and the FY2021 annual result came in at $31.4 million, up 54.35% from the prior year.
- Long-Term Deferred Tax climbed to $31.4 million in Q4 2021, from $20.4 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $31.4 million in Q4 2021 to a low of $71283.0 in Q4 2017.
- A 5-year average of $11.3 million and a median of $4.4 million in 2018 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2017 — Long-Term Deferred Tax soared 52902.22% — and 2019, when it sank 93.52%.
- Tracing PCSA's Long-Term Deferred Tax over 5 years: stood at $71283.0 in 2017, then soared by 6030.07% to $4.4 million in 2018, then slumped by 93.52% to $283189.0 in 2019, then soared by 7089.95% to $20.4 million in 2020, then surged by 54.35% to $31.4 million in 2021.
- The last three Long-Term Deferred Tax figures came in at $31.4 million (Q4 2021), $20.4 million (Q4 2020), and $283189.0 (Q4 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - |
| 10 | Processa Pharmaceuticals | 5.78 Mn | 5.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 31.43 Mn |
| Dec 31, 2020 | 20.36 Mn |
| Dec 31, 2019 | 283,189.00 |
| Dec 31, 2018 | 4.37 Mn |
| Dec 31, 2017 | 71,283.00 |
| Dec 31, 2016 | -135.00 |
| Dec 31, 2015 | 4.99 Mn |
| Dec 31, 2014 | 3.56 Mn |
| Dec 31, 2013 | 66,633.00 |
| Dec 31, 2012 | 1.18 Mn |